10333 related articles for article (PubMed ID: 1525406)
1. Anti-tumor effect of electrotherapy alone or in combination with interleukin-2 in mice with sarcoma and melanoma tumors.
Sersa G; Miklavcic D; Batista U; Novaković S; Bobanović F; Vodovnik L
Anticancer Drugs; 1992 Jun; 3(3):253-60. PubMed ID: 1525406
[TBL] [Abstract][Full Text] [Related]
2. Antitumor effectiveness of different amounts of electrical charge in Ehrlich and fibrosarcoma Sa-37 tumors.
Ciria HC; Quevedo MS; Cabrales LB; Bruzón RP; Salas MF; Pena OG; González TR; López DS; Flores JM
BMC Cancer; 2004 Nov; 4():87. PubMed ID: 15566572
[TBL] [Abstract][Full Text] [Related]
3. Host's immune response in electrotherapy of murine tumors by direct current.
Miklavcic D; An D; Belehradek J; Mir LM
Eur Cytokine Netw; 1997 Sep; 8(3):275-9. PubMed ID: 9346361
[TBL] [Abstract][Full Text] [Related]
4. Potentiation of bleomycin antitumor effectiveness by electrotherapy.
Sersa G; Novaković S; Miklavcic D
Cancer Lett; 1993 Apr; 69(2):81-4. PubMed ID: 7684316
[TBL] [Abstract][Full Text] [Related]
5. Combined local hyperthermia and immunotherapy treatment of an experimental subcutaneous murine melanoma.
Geehan DM; Fabian DF; Lefor AT
J Surg Oncol; 1995 May; 59(1):35-9. PubMed ID: 7745975
[TBL] [Abstract][Full Text] [Related]
6. Anti-tumor effect of tumor necrosis factor combined with electrotherapy on mouse sarcoma.
Sersa G; Golouh R; Miklavcic D
Anticancer Drugs; 1994 Feb; 5(1):69-74. PubMed ID: 8186433
[TBL] [Abstract][Full Text] [Related]
7. Pulsing of dendritic cells with cell lysates from either B16 melanoma or MCA-106 fibrosarcoma yields equally effective vaccines against B16 tumors in mice.
DeMatos P; Abdel-Wahab Z; Vervaert C; Hester D; Seigler H
J Surg Oncol; 1998 Jun; 68(2):79-91. PubMed ID: 9624036
[TBL] [Abstract][Full Text] [Related]
8. Synergistic effects of combination therapy with human recombinant interleukin-2 and tumor necrosis factor in murine tumor models.
Winkelhake JL; Stampfl S; Zimmerman RJ
Cancer Res; 1987 Aug; 47(15):3948-53. PubMed ID: 3496953
[TBL] [Abstract][Full Text] [Related]
9. Tumor necrosis factor alpha mediates the antitumor effect of combined interleukin-2 and whole body hyperthermia.
Fritz KL; Koziol S; Fabian DF; Lefor AT
J Surg Res; 1996 Jan; 60(1):55-60. PubMed ID: 8592432
[TBL] [Abstract][Full Text] [Related]
10. Sequential chemoimmunotherapy with cisplatin, interferon-beta and interleukin-2 inhibits the growth of B16-F1 melanoma in syngeneic mice.
Kubo H; Matsumoto K; Funahashi M; Takagi H; Kitajima Y; Taniguchi S; Saida T
Melanoma Res; 2000 Jun; 10(3):223-9. PubMed ID: 10890375
[TBL] [Abstract][Full Text] [Related]
11. Potentiation of immunologic responsiveness to dendritic cell-based tumor vaccines by recombinant interleukin-2.
Shimizu K; Fields RC; Redman BG; Giedlin M; Mulé JJ
Cancer J Sci Am; 2000 Feb; 6 Suppl 1():S67-75. PubMed ID: 10685663
[TBL] [Abstract][Full Text] [Related]
12. Successful adoptive immunotherapy of murine poorly immunogenic tumor with specific effector cells generated from gene-modified tumor-primed lymph node cells.
Tanaka H; Yoshizawa H; Yamaguchi Y; Ito K; Kagamu H; Suzuki E; Gejyo F; Hamada H; Arakawa M
J Immunol; 1999 Mar; 162(6):3574-82. PubMed ID: 10092816
[TBL] [Abstract][Full Text] [Related]
13. Eradication of mouse melanoma by combined treatment with recombinant human interleukin 2 and recombinant murine interferon-gamma.
Silagi S; Dutkowski R; Schaefer A
Int J Cancer; 1988 Feb; 41(2):315-22. PubMed ID: 3123404
[TBL] [Abstract][Full Text] [Related]
14. Ex vivo and in vivo adenovirus-mediated gene therapy strategies induce a systemic anti-tumor immune defence in the B16 melanoma model.
Bonnekoh B; Greenhalgh DA; Chen SH; Block A; Rich SS; Krieg T; Woo SL; Roop DR
J Invest Dermatol; 1998 Jun; 110(6):867-71. PubMed ID: 9620291
[TBL] [Abstract][Full Text] [Related]
15. Tumor regression by combined immunotherapy and hyperthermia using magnetic nanoparticles in an experimental subcutaneous murine melanoma.
Ito A; Tanaka K; Kondo K; Shinkai M; Honda H; Matsumoto K; Saida T; Kobayashi T
Cancer Sci; 2003 Mar; 94(3):308-13. PubMed ID: 12824927
[TBL] [Abstract][Full Text] [Related]
16. NK and CD8+ T cell-mediated eradication of poorly immunogenic B16-F10 melanoma by the combined action of IL-12 gene therapy and 4-1BB costimulation.
Xu D; Gu P; Pan PY; Li Q; Sato AI; Chen SH
Int J Cancer; 2004 Apr; 109(4):499-506. PubMed ID: 14991570
[TBL] [Abstract][Full Text] [Related]
17. Perturbation of blood flow as a mechanism of anti-tumour action of direct current electrotherapy.
Jarm T; Cemazar M; Steinberg F; Streffer C; Sersa G; Miklavcic D
Physiol Meas; 2003 Feb; 24(1):75-90. PubMed ID: 12636188
[TBL] [Abstract][Full Text] [Related]
18. Augmented antitumor effects of combination therapy with interleukin-12, cisplatin, and tumor necrosis factor-alpha in a murine melanoma model.
Zagozdzon R; Stokłosa T; Gołab J; Giermasz A; Dabrowska A; Lasek W; Jakóbisiak M
Anticancer Res; 1997; 17(6D):4493-8. PubMed ID: 9494557
[TBL] [Abstract][Full Text] [Related]
19. Paracrine immunotherapy with interleukin-2 and local chemotherapy is synergistic in the treatment of experimental brain tumors.
Sampath P; Hanes J; DiMeco F; Tyler BM; Brat D; Pardoll DM; Brem H
Cancer Res; 1999 May; 59(9):2107-14. PubMed ID: 10232596
[TBL] [Abstract][Full Text] [Related]
20. Intracerebral versus subcutaneous immunization with allogeneic fibroblasts genetically engineered to secrete interleukin-2 in the treatment of central nervous system glioma and melanoma.
Glick RP; Lichtor T; Mogharbel A; Taylor CA; Cohen EP
Neurosurgery; 1997 Oct; 41(4):898-906; discussion 906-7. PubMed ID: 9316052
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
